Pricing Log in Create free account
Saturday 17 October 2026 Export ATXI’s income statement to Excel — free account

Avenue Therapeutics, Inc.

ATXI Healthcare Biotechnology

Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million. In the quarter to June 2026, EPS fell 290.9% and free cash flow fell 169.9%, each against the same quarter a year earlier.

0.43 0.00 0.00%
Market cap
$680.0K
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
n/a
Altman Z
−51.47
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 59.03%

Capital & Financial Ratios $m

Market Cap 0.68
Revenue —
Net Income (2.80)
Free Cash Flow (1.38)
Net Debt (1.94)
Current Ratio 1.40
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.43) (negative: loss-making)
P/S ratio 0.00
P/B ratio 2.49
Past 5Y EPS Growth —
This Y EPS Growth 91.51% (at or above 15%: strong)
Next Y EPS Growth 68.59% (at or above 15%: strong)
Next Y revenue growth —
Next 5Y EPS Growth 70.75% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 45.59%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 2 3 3 2
Receivables — — — —
Inventory — — — —
Other — — — —
2 3 3 2
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other 1 0 0 —
1 1 1 1

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value 0.00% (4.93%) (17.53%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 (1) 0 0 (1) (2)
’24 (3) (2) (3) (1) (9)
’23 (2) (5) (1) (2) (9)
’22 (2) (1) (1) (4) (8)
’21 (1) (1) (1) (1) (4)
’20 (1) (1) (1) (1) (5)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 (1) 0 0 (1) (2)
’24 (3) (2) (3) (1) (9)
’23 (2) (5) (1) (2) (9)
’22 (2) (1) (1) (4) (8)
’21 (1) (1) (1) (1) (4)
’20 (1) (1) (1) (1) (5)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.21) (0.21) — — —
’25 (0.62) 0.11 (0.21) (0.22) (0.93)
’24 (7.74) (6.43) (1.92) 1.48 (9.03)
’23 (103.01) (39.10) 4.51 42.11 (73.68)
’22 (157.82) (33.82) (33.83) 92.48 (122.56)
’21 (67.63) (67.63) (56.36) (56.36) (248.00)
’20 (90.18) (124.00) (67.63) (67.63) (349.45)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — 3,825.00 2,340.45 4,646.25 3,206.25 990.00 79.50 9.77 1.60 0.17

Analyst estimates 2026–2028

Powerpack
High — 9,652.50 6,750.00 11,025.00 13,882.27 8,651.25 1,406.25 176.25 26.47 2.23
People
People Employees 3 2 6 4 4 4 2 3 2 1
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.40
Income, $m
Income, $m Revenue — — — — — — — — — 1
Gross margin, % — — — — — — — — — 100.00
EBT (3) (12) (22) (26) (5) (4) (4) (10) (12) (3)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (209.90)
Net income (3) (12) (22) (26) (5) (4) (4) (10) (12) (3)
Depreciation 0 0 — — — — — — — —
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45
Earnings (1,251.76) (2,085.42) (2,367.24) (1,859.97) (349.45) (248.00) (122.56) (73.68) (9.03) (0.93)
Cash flow (652.80) (1,152.88) (2,001.76) (1,889.14) (315.96) (248.34) (261.03) (67.03) (6.97) (0.59)
Capex 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow (652.80) (1,152.88) (2,001.76) (1,889.14) (315.96) (248.34) (261.03) (67.03) (6.97) (0.59)
Book value (3,299.20) 3,284.75 (69.34) 489.21 161.58 228.54 112.23 4.64 1.43 0.59
Shares, m 0 0 0 0 0 0 0 0 1 3
Valuation, ×
Valuation, × P/E — — — — — — — — — 0.00
P/S — — — — — — — — — 0.00
P/B — — — — — — — — — 1.16
EV/Sales — — — — — — — — — 0.00
EV/FCF — — — — — — — — — 0.18
Cash, $m
Cash, $m Operating cash flow (2) (7) (18) (26) (5) (4) (8) (9) (9) (2)
Capex — — — — — — — — — —
Free cash flow (2) (7) (18) (26) (5) (4) (8) (9) (9) (2)
Balance, $m
Balance, $m Working capital (6) 19 (1) 7 2 3 3 1 2 2
Total debt 2 — — — — — — — — —
Net debt 2 (22) (3) (9) (3) (4) (7) (2) (3) (3)
Shareholders’ equity (8) 19 (1) 7 2 3 3 1 2 2
Returns, %
Returns, % ROA (3,011.37) (109.61) (161.44) (385.54) (84.72) (103.57) (65.75) (238.69) (515.35) (103.84)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE 47.48 (220.23) (229.86) (839.94) (112.48) (128.43) (105.76) (529.44) (928.45) (157.75)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2025

Charts ten years each

Avenue Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CRIS Curis, Inc. $1.1M — (loss-making) — (loss-making) −65.98% (below 0%: shrinking) n/m −20.44% (below 0%: shrinking) 100.00% 0.00% Compare
MNTRQ 9 Meters Biopharma, Inc. $1.0M — (loss-making) — −25.99% (below 0%: shrinking) n/m +0.01% (above 0%: growing) 0.00% 0.00% Compare
ZVSA ZyVersa Therapeutics, Inc. $970.0K — (loss-making) — — n/m +54.91% (above 0%: growing) 0.00% 0.00% Compare
LYRA Lyra Therapeutics, Inc. $870.0K — (loss-making) — (loss-making) −96.65% (below 0%: shrinking) n/m +45.44% (above 0%: growing) 100.00% (101,685.71%) Compare
BTTX Better Therapeutics, Inc. $850.0K — (loss-making) — — n/m +20.43% (above 0%: growing) 0.00% 0.00% Compare
SEELQ Seelos Therapeutics, Inc. $700.0K — (loss-making) — (loss-making) +11.90% (above 0%: growing) n/m +83.54% (above 0%: growing) 100.00% (834.84%) Compare
ATXI Avenue Therapeutics, Inc. $680.0K — (loss-making) — (loss-making) — n/m −169.89% (below 0%: shrinking) 100.00% 0.00%
SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR $640.0K 0.0× — (loss-making) — n/m +51.13% (above 0%: growing) (228.63%) (504.50%) Compare
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR $440.0K — (loss-making) — −32.27% (below 0%: shrinking) +96.36% (above 0%: growing) −0.17% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $860.0K — — −32.27% — +32.94% 0.00% 0.00%

All 614 Biotechnology stocks →

Avenue Therapeutics, Inc. (ATXI) key facts

  • Avenue Therapeutics, Inc. (ATXI) is a Biotechnology company in the Healthcare sector.
  • Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million.
  • As of October 15, 2026, ATXI traded at $0.43, a market capitalization of $680,000.00.
  • Return on equity was −157.8% and debt-to-equity 0.00.
  • Its Altman Z-score is −51.47 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Avenue Therapeutics, Inc. (ATXI) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ATXI · Data as of Jun 30, 2025 · For information only; not investment advice. · © 2026 stockrow.com